Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Conclusions Ilorasertib exhibited acceptable safety and pharmacokinetics at or below the recommended phase 2 dose, displayed evidence of dual Aurora kinase and VEGF receptor kinase inhibition, and activity in AML.

http://link.springer.com/10.1007/s10637-015-0242-6

Source: Investigational New Drugs - May 2, 2015 Category: Drugs & Pharmacology Source Type: research